Clonality analysis of pulmonary tumors by genome-wide copy number profiling


Autoři: Julien P. L. Vincenten aff001;  Hendrik F. van Essen aff003;  Birgit I. Lissenberg-Witte aff004;  Nicole W. J. Bulkmans aff005;  Oscar Krijgsman aff006;  Daoud Sie aff003;  Paul P. Eijk aff003;  Egbert F. Smit aff001;  Bauke Ylstra aff003;  Erik Thunnissen aff008
Působiště autorů: Amsterdam UMC, location VUmc, Department of Pulmonary Diseases, Amsterdam, The Netherlands aff001;  Albert Schweitzer Hospital, Department of Pulmonary Diseases, Dordrecht, The Netherlands aff002;  Amsterdam UMC, location VUmc, Tumor Genome Analysis Core, Cancer Center Amsterdam, The Netherlands aff003;  Amsterdam UMC, location VUmc, Department of Epidemiology and Biostatistics, Amsterdam, The Netherlands aff004;  Spaarne Gasthuis, Department of Pathology, Haarlem, The Netherlands aff005;  Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Molecular Oncology & Immunology, Amsterdam, The Netherlands aff006;  Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Thoracic Oncology, Amsterdam, The Netherlands aff007;  Amsterdam UMC, location VUmc, Department of Pathology, Amsterdam, The Netherlands aff008
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223827

Souhrn

Multiple tumors in patients are frequently diagnosed, either synchronous or metachronous. The distinction between a second primary and a metastasis is important for treatment. Chromosomal DNA copy number aberrations (CNA) patterns are highly unique to specific tumors. The aim of this study was to assess genome-wide CNA-patterns as method to identify clonally related tumors in a prospective cohort of patients with synchronous or metachronous tumors, with at least one intrapulmonary tumor. In total, 139 tumor pairs from 90 patients were examined: 35 synchronous and 104 metachronous pairs. Results of CNA were compared to histological type, clinicopathological methods (Martini-Melamed-classification (MM) and ACCP-2013-criteria), and, if available, EGFR- and KRAS-mutation analysis. CNA-results were clonal in 74 pairs (53%), non-clonal in 33 pairs (24%), and inconclusive in 32 pairs (23%). Histological similarity was found in 130 pairs (94%). Concordance between histology and conclusive CNA-results was 69% (74 of 107 pairs: 72 clonal and two non-clonal). In 31 of 103 pairs with similar histology, genetics revealed non-clonality. In two out of four pairs with non-matching histology, genetics revealed clonality. The subgroups of synchronous and metachronous pairs showed similar outcome for the comparison of histological versus CNA-results. MM-classification and ACCP-2013-criteria, applicable on 34 pairs, and CNA-results were concordant in 50% and 62% respectively. Concordance between mutation matching and conclusive CNA-results was 89% (8 of 9 pairs: six clonal and two non-clonal). Interestingly, in one patient both tumors had the same KRAS mutation, but the CNA result was non-clonal. In conclusion, although some concordance between histological comparison and CNA profiling is present, arguments exist to prefer extensive molecular testing to determine whether a second tumor is a metastasis or a second primary.

Klíčová slova:

Adenocarcinoma of the lung – Adenocarcinomas – Histology – Lung and intrathoracic tumors – Metastasis – Non-small cell lung cancer – Secondary lung tumors – Squamous cell lung carcinoma


Zdroje

1. Flieder DB, Vazquez M, Carter D, Brambilla E, Gazdar A, Noguchi M, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol 2006; 30:606–13. doi: 10.1097/01.pas.0000202040.51967.d0 16699315

2. Ripley RT, McMillan RR, Sima CS, Hasan SM, Ahmad U, Lou F, et al. Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg 2014; 98:968–74. doi: 10.1016/j.athoracsur.2014.04.098 25038021

3. Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 2013; 145:75–81. doi: 10.1016/j.jtcvs.2012.09.030 23127371

4. Milano MT, Peterson CR, Zhang H, Singh DP, Chen Y. Second primary lung cancer after head and neck squamous cell cancer: population-based study of risk factors. Head Neck 2012; 34:1782–8. doi: 10.1002/hed.22006 22319019

5. Griffioen GHMJ, Louie AV, de Bree R, Smit EF, Paul MA, Slotman BJ, et al. Second primary lung cancers following a diagnosis of primary head and neck cancer. Lung Cancer 2015; 88:94–9. doi: 10.1016/j.lungcan.2015.01.011 25662386

6. Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist LV, Ireland B, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e341S–e368S. doi: 10.1378/chest.12-2361 23649446

7. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975; 70:606–12. 170482

8. Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e369S–e399S. doi: 10.1378/chest.12-2362 23649447

9. Shimizu S, Yatabe Y, Koshikawa T, Haruki N, Hatooka S, Shinoda M, et al. High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res 2000; 6:3994–9. 11051248

10. Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009; 15:5184–90. doi: 10.1158/1078-0432.CCR-09-0594 19671847

11. Wu C, Zhao C, Yang Y, He Y, Hou L, Li X, et al. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. J Thorac Oncol 2015; 10:778–83. doi: 10.1097/JTO.0000000000000487 25629635

12. Wu CT, Lin MW, Hsieh MS, Kuo SW, Chang YL. New aspects of the clinicopathology and genetic profile of metachronous multiple lung cancers. Ann Surg 2014; 259:1018–24. doi: 10.1097/SLA.0000000000000385 24368645

13. Lin MW, Wu CT, Kuo SW, Chang YL, Yang PC. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy. Ann Surg Oncol 2014; 21:2555–62. doi: 10.1245/s10434-014-3642-5 24643899

14. Warth A, her-Goeppinger S, Muley T, Thomas M, Hoffmann H, Schnabel PA, et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J 2012; 39:1437–42. doi: 10.1183/09031936.00105911 22075483

15. Wang X, Wang M, MacLennan GT, bdul-Karim FW, Eble JN, Jones TD, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst 2009; 101:560–70. doi: 10.1093/jnci/djp054 19351924

16. Secker-Walker LM. The meaning of a clone. Cancer Genet Cytogenet 1985; 16:187–8. doi: 10.1016/0165-4608(85)90015-9 3971342

17. Shiseki M, Kohno T, Nishikawa R, Sameshima Y, Mizoguchi H, Yokota J. Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res 1994; 54:5643–8. 7923210

18. Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998; 90:972–7. doi: 10.1093/jnci/90.13.972 9665144

19. Kuhn E, Teller L, Piana S, Rosai J, Merino MJ. Different clonal origin of bilateral papillary thyroid carcinoma, with a review of the literature. Endocr Pathol 2012; 23:101–7. doi: 10.1007/s12022-012-9202-2 22434481

20. Banelli B, Casciano I, Di Vinci A, Gatteschi B, Levaggi A, Carli F, et al. Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. Ann Oncol 2010; 21:1237–42. doi: 10.1093/annonc/mdp470 19875753

21. Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol 2013; 31:2167–72. doi: 10.1200/JCO.2012.47.7737 23630207

22. Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011; 12:380–6. doi: 10.1016/j.cllc.2011.02.006 21729655

23. Chung JH, Choe G, Jheon S, Sung SW, Kim TJ, Lee KW, et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 2009; 4:1490–5. doi: 10.1097/JTO.0b013e3181bc9731 19844187

24. Arai J, Tsuchiya T, Oikawa M, Mochinaga K, Hayashi T, Yoshiura KI, et al. Clinical and molecular analysis of synchronous double lung cancers. Lung Cancer 2012; 77:281–7. doi: 10.1016/j.lungcan.2012.04.003 22560922

25. Jiang JK, Chen YJ, Lin CH, Yu IT, Lin JK. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases—an analysis by comparative genomic hybridization. Genes Chromosomes Cancer 2005; 43:25–36. doi: 10.1002/gcc.20167 15723340

26. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer 2000; 82:65–73. doi: 10.1054/bjoc.1999.0878 10638968

27. Moffatt-Bruce SD, Ross P, Leon ME, He G, Finkelstein SD, Vaida AM, et al. Comparative mutational profiling in the assessment of lung lesions: should it be the standard of care? Ann Thorac Surg 2010; 90:388–96. doi: 10.1016/j.athoracsur.2010.03.059 20667316

28. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15:4554–60. doi: 10.1158/1078-0432.CCR-09-0089 19584155

29. Gallegos Ruiz MI, van Cruijsen H, Smit EF, Grunberg K, Meijer GA, Rodriguez JA, et al. Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases. J Thorac Oncol 2007; 2:12–21. 17410004

30. Groenendijk MR, Thunnissen E, Ylstra B, van de Wiel MA, Eijk PP, Paul MA, et al. An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary? J Thorac Oncol 2012; 7:e3–e5. doi: 10.1097/JTO.0b013e31825bcead 22797153

31. ter Avest MJ, Schook RM, Postmus PE, Grunberg K, Ylstra B, Paul MA. Benefit of a second opinion: intrapulmonary metastases or multiple primary tumors? J Thorac Oncol 2013; 8:e54–e56. doi: 10.1097/JTO.0b013e31828c28c6 23676562

32. Ostrovnaya I, Olshen AB, Seshan VE, Orlow I, Albertson DG, Begg CB. A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Stat Med 2010; 29:1608–21. doi: 10.1002/sim.3866 20205270

33. Bertrand A, Rondenet C, Masliah-Planchon J, Leblond P, de la Fourchardiere A, Pissaloux D, et al. Rhabdoid component emerging as a subclonal evolution of paediatric glioneuronal tumours. Neuropathol Appl Neurobiol 2018; 44:224–8. doi: 10.1111/nan.12379 28054381

34. Juskevicius D, Lorber T, Gsponer J, Perrina V, Ruiz C, Stenner-Liewen F, et al. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia 2016; 30:2385–95. doi: 10.1038/leu.2016.135 27198204

35. Qiu ZW, Bi JH, Gazdar AF, Song K. Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer. Genes Chromosomes Cancer 2017; 56:559–69. doi: 10.1002/gcc.22460 28379620

36. Detterbeck FC, Franklin WA, Nicholson AG, Girard N, Arenberg DA, Travis WD, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:651–65. doi: 10.1016/j.jtho.2016.01.025 26944304

37. Vincenten JPL, Smit EF, Grunberg K, Postmus PE, Snijders PJF, Witte BI, et al. Is the current diagnostic algorithm reliable for selecting cases for. Lung Cancer 2015; 89:19–26. doi: 10.1016/j.lungcan.2015.04.005 25982011

38. Travis William D., Brambilla E., Muller-Hermelink H. Konrad Harris Curtis C., and (Eds) (2004) World Health Organization. Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.

39. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244–85. doi: 10.1097/JTO.0b013e318206a221 21252716

40. Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et al. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol 2019; 14:377–407. doi: 10.1016/j.jtho.2018.12.005 30572031

41. Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012; 25:1574–83. doi: 10.1038/modpathol.2012.106 22814311

42. Kawaguchi T. Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates. Cardiovasc Hematol Disord Drug Targets 2016; 15:164–86. 26521885

43. van Essen HF, Ylstra B. High-resolution copy number profiling by array CGH using DNA isolated from formalin-fixed, paraffin-embedded tissues. Methods Mol Biol 2012; 838:329–41. doi: 10.1007/978-1-61779-507-7_16 22228020

44. Buffart TE, Tijssen M, Krugers T, Carvalho B, Smeets SJ, Brakenhoff RH, et al. DNA quality assessment for array CGH by isothermal whole genome amplification. Cell Oncol 2007; 29:351–9. doi: 10.1155/2007/709290 17641418

45. van de Wiel MA, Picard F, van Wieringen WN, Ylstra B. Preprocessing and downstream analysis of microarray DNA copy number profiles. Brief Bioinform 2011; 12:10–21. doi: 10.1093/bib/bbq004 20172948

46. Ostrovnaya I, Seshan VE, Olshen AB, Begg CB. Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics 2011; 27:1698–9. doi: 10.1093/bioinformatics/btr267 21546399

47. Mekenkamp LJM, Haan JC, Israeli D, van Essen HFB, Dijkstra JR, van Cleef P, et al. Chromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent. PLoS One 2014; 9:e86833. doi: 10.1371/journal.pone.0086833 24505270

48. Chari R, Lockwood W, Lam W. Computational Methods for the Analysis of Array Comparative Genomic Hybridization. Cancer Inform 2006; 2:48–58.

49. Sie D, Snijders PJF, Meijer GA, Doeleman MW, van Moorsel MIH, van Essen HF, et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr) 2014; 37:353–61.

50. Carvalho B, Buffart TE, Reis RM, Mons T, Moutinho C, Silva P, et al. Mixed gastric carcinomas show similar chromosomal aberrations in both their diffuse and glandular components. Cell Oncol 2006; 28:283–94. doi: 10.1155/2006/650620 17167181

51. Vekony H, Leemans CR, Ylstra B, Meijer GA, van der Waal I, Bloemena E. Salivary gland carcinosarcoma: oligonucleotide array CGH reveals similar genomic profiles in epithelial and mesenchymal components. Oral Oncol 2009; 45:259–65. doi: 10.1016/j.oraloncology.2008.05.009 18693132

52. Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009; 33:1752–64. doi: 10.1097/PAS.0b013e3181b8cf03 19773638

53. Zhang Y, Hu H, Wang R, Ye T, Pan Y, Wang L, et al. Synchronous non-small cell lung cancers: diagnostic yield can be improved by histologic and genetic methods. Ann Surg Oncol 2014; 21:4369–74. doi: 10.1245/s10434-014-3840-1 25081337

54. Murphy SJ, Aubry MC, Harris FR, Halling GC, Johnson SH, Terra S, et al. Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. J Clin Oncol 2014; 32:4050–8. doi: 10.1200/JCO.2014.56.7644 25385739

55. Schneider F, Derrick V, Davison JM, Strollo D, Incharoen P, Dacic S. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Mod Pathol 2016; 29:735–42. doi: 10.1038/modpathol.2016.66 27080983

56. Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, et al. Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 2018; 13:205–17. doi: 10.1016/j.jtho.2017.10.019 29127023

57. Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest 2010; 137:46–52. doi: 10.1378/chest.09-0325 19376842

58. Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res 2011; 30:30. doi: 10.1186/1756-9966-30-30 21414214

59. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14:5731–4. doi: 10.1158/1078-0432.CCR-08-0646 18794081

60. Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. Cancer 2013; 119:2268–74. doi: 10.1002/cncr.28039 23526491

61. Dogan S, Shen R, Ang DC, Johnson ML, D’Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012; 18:6169–77. doi: 10.1158/1078-0432.CCR-11-3265 23014527

62. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346:251–6. doi: 10.1126/science.1253462 25301630

63. Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun 2016; 7:13200. doi: 10.1038/ncomms13200 27767028

64. Lovly C, Horn L, Pao W. Molecular Profiling of Lung Cancer. My Cancer Genome. https://www.mycancergenome.org/content/disease/lung-cancer/. (March) 2018

65. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883–92. doi: 10.1056/NEJMoa1113205 22397650

66. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376:2109–21. doi: 10.1056/NEJMoa1616288 28445112

67. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387:1415–26. doi: 10.1016/S0140-6736(16)00004-0 26777916

68. Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gruning W, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open 2013; 3.

69. Schuette W, Schirmacher P, Eberhardt WEE, Fischer JR, von der Schulenburg JMG, Mezger J, et al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Biomarkers Prev 2015; 24:1254–61. doi: 10.1158/1055-9965.EPI-14-1149 26070531

70. Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Domine M, Gomez Aldaravi L, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol 2015; 39:291–7. doi: 10.1016/j.canep.2015.02.003 25766256

71. Krijgsman O, Israeli D, van Essen HF, Eijk PP, Berens MLM, Mellink CHM, et al. Detection limits of DNA copy number alterations in heterogeneous cell populations. Cell Oncol (Dordr) 2013; 36:27–36.

72. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 2014; 24:2022–32. doi: 10.1101/gr.175141.114 25236618

73. Macintyre G, Ylstra B, Brenton JD. Sequencing Structural Variants in Cancer for Precision Therapeutics. Trends Genet 2016; 32:530–42. doi: 10.1016/j.tig.2016.07.002 27478068

74. Liang WS, Aldrich J, Tembe W, Kurdoglu A, Cherni I, Phillips L, et al. Long insert whole genome sequencing for copy number variant and translocation detection. Nucleic Acids Res 2014; 42:e8. doi: 10.1093/nar/gkt865 24071583

75. Oepkes D, Page-Christiaens GCL, Bax CJ, Bekker MN, Bilardo CM, Boon EMJ, et al. Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact. Prenat Diagn 2016; 36:1083–90. doi: 10.1002/pd.4945 27750376

76. Mazzola R, Fersino S, Ferrera G, Targher G, Figlia V, Triggiani L, et al. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Med Oncol 2018; 35:121. doi: 10.1007/s12032-018-1190-8 30076479

77. Kwint M, Walraven I, Burgers S, Hartemink K, Klomp H, Knegjens J, et al. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. Lung Cancer 2017; 112:134–9. doi: 10.1016/j.lungcan.2017.08.006 29191586

78. Mazzola R, Fersino S, Ferrera G, Targher G, Figlia V, Triggiani L, et al. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Med Oncol 2018; 35:121. doi: 10.1007/s12032-018-1190-8 30076479

79. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest 2017; 151:193–203. doi: 10.1016/j.chest.2016.10.010 27780786


Článek vyšel v časopise

PLOS One


2019 Číslo 10